The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved
Open accessAbstract
It is not uncommon for new anti-cancer drugs or therapies to show highly effective, and sometimes even spectacular anti-cancer treatment results using transplantable tumors in mice. These models frequently involve human tumor xenografts grown subcutaneously in immune deficient hosts such as athymic (nude) or severe combined immune deficient (SCID) mice. Unfortunately, such preclinical results are often followed by failure of the drug/therapy in clinical trials, or, if the drug is successful, it usually has only modest efficacy results, by comparison. Not surprisingly, this has provoked considerable skepticism about the value of using such preclinical models for early stage in vivo preclinical drug testing. As a result, a shift has occurred towards developing and using spontaneous mouse tumors arising in transgenic and/or knockout mice engineered to recapitulate various genetic alterations thought to be causative of specific types of respective human cancers. Alternatively, the opinion has been expressed of the need to refine and improve the human tumor xenograft models, e.g., by use of orthotopic transplantation and therefore promotion of metastatic spread of the resultant "primary" tumors. Close inspection of retrospective and prospective studies in the literature, however, reveals that human tumor xenografts-even non metastatic ectopic/subcutaneous "primary" tumor transplants-can be remarkably predictive of cytotoxic chemotherapeutic drugs that have activity in humans, when the drugs are tested in mice using pharmacokinetically clinically equivalent or "rational" drug doses. What may be at variance with clinical activity, however, is the magnitude of the benefit observed in mice, both in terms of the degree of tumor responses and overall survival. It is argued that this disparity can be significantly minimized by use of orthotopic transplant/metastatic tumor models in which treatment is initiated after the primary tumor has been removed and the distant metastases are well established and macroscopic-i.e., the bar is raised and treatment is undertaken on advanced, high volume, metastatic disease. In such circumstances, survival should be used as an endpoint; changes in tumor burden using surrogate markers or micro-imaging techniques can be used as well to monitor effects of therapies on tumor response. Adoption of such procedures would more accurately recapitulate the phase I/II/III clinical trial situation in which treatment is initiated on patients with advanced, high-volume metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationLess is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Fidler, I. J. (1986) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00049529 · Cited by 373
A cancer therapy resistant to resistance
Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 369
Self-citationCancer Modeling in the Modern Era
Van Dyke, T., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 358
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Self-citation
Cited by
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
The use of 3-d cultures for high-throughput screening: the multicellular spheroid model.
Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F., & Ebner, R. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104265040 · Cited by 797
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3281 · Cited by 694
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer
Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060929 · Cited by 468
Mouse xenograft models vs GEM models for human cancer therapeutics
Richmond, A., & Su, Y. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000976 · Cited by 467
Daniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4210 · Cited by 467
Animal models in translational medicine: Validation and prediction
Denayer, T., Stöhr, T., & Roy, M. V. (2014) · European Journal of Molecular & Clinical Medicine · doi:10.1016/j.nhtm.2014.08.001 · Cited by 448
Experimental anti-tumor therapy in 3-D: Spheroids – old hat or new challenge?
Friedrich, J., Ebner, R., & Kunz-Schughart, L. A. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701727531 · Cited by 446
Mouse models of advanced spontaneous metastasis for experimental therapeutics
Francia, G., Cruz-Munoz, W., Man, S., Xu, P., & Kerbel, R. S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3001 · Cited by 374
Self-citationChen, S., Zhong, Y., Fan, W., Xiang, J., Wang, G., Zhou, Q., Wang, J., Geng, Y., Sun, R., Zhang, Z., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00701-4 · Cited by 325
The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
Jung, J., Seol, H. S., & Chang, S. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.307 · Cited by 310
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., & Maitra, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0152 · Cited by 296
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
Self-citationIn vivo models of primary brain tumors: pitfalls and perspectives
Huszthy, P. C., Daphu, I., Niclou, S. P., Stieber, D., Nigro, J. M., Sakariassen, P. O., Miletic, H., Thorsen, F., & Bjerkvig, R. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos135 · Cited by 282
MMPs as therapeutic targets—Still a viable option?
FINGLETON, B. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2007.06.006 · Cited by 279
Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.233.3.3 · Cited by 240
Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125
Targeted Oral Delivery of Paclitaxel Using Colostrum-Derived Exosomes
Kandimalla, R., Aqil, F., Alhakeem, S., Jeyabalan, J., Tyagi, N., Agrawal, A., Yan, J., Spencer, W., Bondada, S., & Gupta, R. (2021) · Cancers · doi:10.3390/cancers13153700 · Cited by 99
Goldstein, S. D., Trucco, M., Guzman, W. B., Hayashi, M., & Loeb, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8522 · Cited by 78
Bocci, G., Danesi, R., Marangoni, G., Fioravanti, A., Boggi, U., Esposito, I., Fasciani, A., Boschi, E., Campani, D., Bevilacqua, G., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.062 · Cited by 49
Metadata
- Authors
- Kerbel, R. S.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2003-03
- Volume
- 2
- Issue
- sup1
- Pages
- 133-138
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2120191503
- Cited by
- 326
- References
- 33
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.